Developed by Masaki Okano and En Li, Massachusetts General Hospital in 2001. J1 ES cells were used to generate the mutant mice. The mutant mice were crossed to C57BL/6. Massachusetts General Hospital・岡野正樹先生、En Li（2001）。J1 ES細胞を用いて作出。 条件を付加する。<br>A. RECIPIENT must send a copy of the executed MTA between RECIPIENT and RIKEN BRC to: Massachusetts General Hospital c/o Partners Innovation, Attn: TAG/MGH MTA 2020A005592, 399 Revolution Drive/Ste 950E, Somerville,MA 02245, USA (phsmta@partners.org). B. Any publication or public disclosure of research results obtained by the use of the BIOLOGICAL RESOURCE shall cite Massachusetts General Hospital in Boston, MA as the source of the material. However, neither the name, trademark, service mark, logo nor other identifying characteristic ("Name") of MGH or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the MGH Department of Public Affairs. C. In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature Nature 2004 429:900-3 as designated by the DEPOSITOR is required. D. The use of the BIOLOGICAL RESOURCE is restricted to academic researchers in non-profit organizations for their internal research and educational purposes. E. The BIOLOGICAL RESOURCE shall not be used for commercial purposes. Any request for the BIOLOGICAL RESOURCE by a for-profit entity shall be referred to Massachusetts General Hospital through the Research and Licensing Office. F. Recipients shall assume all liability for their use, storage, handling and disposal of the BIOLOGICAL RESOURCE. The General Hospital Corporation d/b/a Massachusetts General Hospital will not be liable to the Recipients for any loss, claims, matters, damages, costs or liabilities relating to any third party actions, proceedings, investigations, or matters arising from any use, storage, handling, or disposal of the BIOLOGICAL RESOURCE by Recipient. Homozygote x Homozygote [or Crossing to C57BL/6JJcl] Homozygote x Homozygote [or Crossing to C57BL/6JJcl] true 岡野　正樹 Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Please use the MATERIAL TRANSFER AGREEMENT for Distribution <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx"> for non-profit</A> or <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c_P.docx"> for profit</A> (English only).</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> B (1-3 months) Phage P1 LoxP sites, mouse Dnmt3a genomic DNA Dnmt3a floxed mice. Exon 19 of Enmt3a that encoding the conserved PC motif of the catalytic domain was flanked by loxP sites. Conditional Dnmt3a deficient mice can be generated by crossing with tissue-specific Cre mice. Homozygous mice are viable and fertile. Dnmt3a knockout mice (RBRC03730), Dnmt3b knockout mice (RBRC03732), Dnmt3b floxed mice (RBRC03733). <a href='https://brc.riken.jp/mus/pcr03731'>Genotyping protocol -PCR-</a> Masaki OKANO RBRC03731 B6;129S4-Dnmt3a<tm3.1Enl> B6;129S4-Dnmt3a<tm3.1Enl> Dnmt3a<tm3.1Enl>; Dnmt3a conditional KO, Dnmt3a-2lox Dnmt3a<tm3.1Enl>; Dnmt3a conditional KO, Dnmt3a-2lox A. RECIPIENT must send a copy of the executed MTA between RECIPIENT and RIKEN BRC to: Massachusetts General Hospital c/o Partners Innovation, Attn: TAG/MGH MTA 2020A005592, 399 Revolution Drive/Ste 950E, Somerville,MA 02245, USA (phsmta@partners.org). B. Any publication or public disclosure of research results obtained by the use of the BIOLOGICAL RESOURCE shall cite Massachusetts General Hospital in Boston, MA as the source of the material. However, neither the name, trademark, service mark, logo nor other identifying characteristic ("Name") of MGH or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the MGH Department of Public Affairs. C. In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature Nature 2004 429:900-3 as designated by the DEPOSITOR is required. D. The use of the BIOLOGICAL RESOURCE is restricted to academic researchers in non-profit organizations for their internal research and educational purposes. E. The BIOLOGICAL RESOURCE shall not be used for commercial purposes. Any request for the BIOLOGICAL RESOURCE by a for-profit entity shall be referred to Massachusetts General Hospital through the Research and Licensing Office. F. Recipients shall assume all liability for their use, storage, handling and disposal of the BIOLOGICAL RESOURCE. The General Hospital Corporation d/b/a Massachusetts General Hospital will not be liable to the Recipients for any loss, claims, matters, damages, costs or liabilities relating to any third party actions, proceedings, investigations, or matters arising from any use, storage, handling, or disposal of the BIOLOGICAL RESOURCE by Recipient. J1 [129S4/SvJae] Dnmt3a遺伝子のfloxedマウス。Dnmt3a遺伝子座の酵素活性に必須なモチーフをコードするエクソンをloxP配列で挟んでおり、適切なCre発現マウスとの交配により、コンディショナルにDnmt3aを不活化することができる。哺乳類は、互いに高いアミノ酸配列類似性のある二つのDe novo型DNAメチル化酵素Dnmt3a、Dnmt3bを持つ。両者は異なるアイソフォーム、発現パターンを示し、互いに重複する機能とそれぞれに特異的な機能を持つ。ホモマウスは通常の維持繁殖には特に問題ない。TNAP-Creトランスジェニックマウスと交配し、生殖細胞特異的にDnmt3aを不活性化すると、ゲノムインプリントが形成されない。Dnmt3aノックアウトマウス (RBRC03730) 、Dnmt3bノックアウトマウス (RBRC03732) 、Dnmt3b floxedマウス (RBRC03733) 。 B（1〜3か月） Cre/loxP system